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Abstract
Serine proteinase inhibitors (Serpins) are irreversible suicide inhibitors of proteases that regulate diverse physiological
processes such as coagulation, fibrinolysis, complement activation, angiogenesis, apoptosis, inflammation, neoplasia and
viral pathogenesis. The molecular structure and physical properties of serpins permit these proteins to adopt a number of
variant conformations under physiological conditions including the native inhibitory form and several inactive, non-
inhibitory forms, such as complexes with protease or other ligands, cleaved, polymerised and oxidised. Alterations of a serpin
which affect its structure and/or secretion and thus reduce its functional levels may result in pathology. Serpin dysfunction
has been implicated in thrombosis, emphysema, liver cirrhosis, immune hypersensitivity and mental disorders. The loss of
inhibitory activity of serpins necessarily results in an imbalance between proteases and their inhibitors, but it may also have
other physiological effects through the generation of abnormal concentrations of modified, non-inhibitory forms of serpins.
Although these forms of inhibitory serpins are detected in tissues and fluids recovered from inflammatory sites, the important
questions of which conditions result in generation of different molecular forms of serpins, what biological function these
forms have, and which of them are directly linked to pathologies and/or may be useful markers for characterisation of disease
states, remain to be answered. Elucidation of the biological activities of non-inhibitory forms of serpins may provide useful
insights into the pathogenesis of diseases and suggest new therapeutic strategies. ß 2001 Published by Elsevier Science B.V.
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1. The serpin superfamily
The regulation of proteolytic enzymes in tissues by
endogenous inhibitors is a prerequisite for the main-
tenance of homeostasis. The proteinase inhibitory
activity of human plasma was recognised in 1894
by Fermi and Pernossi [1]. The main inhibitor re-
sponsible for antiproteolytic activity was ¢rst isolated
in 1955 by Shultze and named K1-antitrypsin (AAT)
because of its ability to inhibit trypsin. Using electro-
phoretic techniques, Laurell and Eriksson 1963 ¢rst
demonstrated the absence of the AAT fraction in a
number of patients’ sera, and showed a relationship
between AAT de¢ciency and chronic degenerative
lung disease [2]. Identi¢cation of the serpin family
of proteins occurred with the recognition that oval-
bumin, AAT and antithrombin share a 30^50% se-
quence homology [3,4]. Genetic characterisation has
revealed a large group of genes belonging to the ser-
pin family that probably arose by gene duplication of
an ancestral gene [5]. The term serpin was later in-
troduced as a general descriptor by Carrell and
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Travis in 1985 for a superfamily of serine proteinase
inhibitors in mammalian blood plasma [6]. Overall,
the serpins have an average of about 30% sequence
identity, increasing to 70% when comparison is lim-
ited to hydrophobic sequences. Thus, there has been
strong conservation of the internal residues of the
serpins, indicating conservation of their tertiary
structure. This has been con¢rmed in the now large
number of serpins whose crystal structures have been
determined.
There are now over 60 members of the serpin fam-
ily occurring widely in higher organisms, and also in
viruses, insects and plants, but not in bacteria and
yeast. The primary function of most of the serpins is
the regulation of proteolytic enzymes under both
physiological and pathological conditions. On the
basis of strong sequence similarities, a number of
proteins with no known inhibitory activity have
been classi¢ed as serpins. For example, thyroxine
binding globulin (TBG) and corticosteroid binding
globulin (CBG) serve as transporters of lipophilic
hormones [7^9], angiotensinogen is a peptide hor-
mone precursor [10], and the more recently described
‘orphan’ ovalbumin serpins have been implicated in
the regulation of cell death [11].
The rapid expansion of the serpin family has per-
mitted further di¡erentiation into subfamilies based
on amino acid sequence. For instance, the ovalbu-
min-type serpin subfamily, which originally included
¢ve serpins (chicken ovalbumin, plasminogen activa-
tor inhibitor (PAI)-2, the squamous cell carcinoma
antigen (SCCA) and leucocyte elastase inhibitor),
now has more than 20 members [12]. More recently
identi¢ed members of the human ovalbumin serpins
include a tumour suppressor and angiogenesis inhib-
itor called maspin [13,14], a bone marrow-associated
inhibitory serpin, bomapin [15] and cytoplasmic anti-
proteinase, also known as proteinase 6 [16]. Myxoma
virus expresses SERP-1, the only known virus-en-
coded serpin that is secreted from infected cells and
has anti-in£ammatory activity although the speci¢c
protease target for SERP-1 that is responsible for its
activity is not known yet [17,18]. Thus, a major chal-
lenge in serpin biology today is not only ¢nding tar-
get proteinases for newly discovered serpins, but also
identi¢cation of the many existing and newly discov-
ered serpins with functions other than proteinase in-
hibition.
2. Structural-functional characteristics of serpins
The irreversibility of proteinase inhibition achieved
by the serpins has made them the principal inhibitors
controlling both intra- and extracellular proteolytic
pathways. Serpins regulate such diverse physiological
processes as coagulation, ¢brinolysis, complement
activation, angiogenesis, apoptosis, in£ammation,
neoplasia and viral pathogenesis. However, their pre-
cise mechanism of action in many of these processes
remains controversial. The primary function of most
members of the serpin family is to neutralise overex-
pressed serine proteinase activity [19]. Therefore, al-
terations of a serpin which a¡ect its structure and/or
secretion and thereby reduce its functional levels,
may result in pathology. Serpin dysfunction has
been implicated in thrombosis, emphysema, cirrhosis,
immune hypersensitivity, mental disorders and in dis-
eases characterised by connective and other tissue
self-destruction [20].
Understanding the lost and altered activities of
these dysfunctional serpins has been greatly ad-
vanced by correlation of molecular structure studies
with analysis of the interaction mechanisms of ser-
pins and their target proteinases, and of their phys-
ical properties. Serpins are irreversible, suicide inhib-
itors of proteinases with a positionally conserved
reactive site that acts as a ‘bait’ for a serine or cys-
teine proteinase [21]. The X-ray crystal structures of
serpins have shown that they are globular proteins
with nine K-helices and three L-sheets. The reac-
tive centre loop is localised in an approx. 20 amino
acid long peptide segment on the molecular surface.
It is linked C-terminally to strand 1 of L-sheet C
and N-terminally to strand 5 of L-sheet A (Fig. 1).
Proteolytic cleavage of the reactive centre loop by
proteinase leads to insertion of the strand N-terminal
to the cleavage site as strand 4 in L-sheet A. This
unique mechanism of inhibition involves a profound
change to a conformation with a higher thermo-
dynamic stability, although the nature and signi¢-
cance of this change has been controversial. The re-
cently reported crystal structure of an K1-antitrypsin
and trypsin complex shows that the reaction of the
protease with the reactive centre of the serpin results
in cleavage the reactive centre of the serpin, and
migration of the proteinase to the opposite pole of
the serpin. This linkage of the two molecules causes
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a large loss of structure in the proteinase [22] in-
duced by serpin-imposed disruption of the active
site and of stabilising intramolecular interactions in
the protease. Earlier studies had found an increase
in proteolytic vulnerability of proteinases in com-
plex with serpins [23^25]. The increased proteolytic
lability of the complex results in localised destruc-
tion of the proteinase before the slower receptor-
mediated uptake from the circulation occurs. Thus,
previous studies on a variety of serpin-proteinase
complexes and the recently resolved structure of a
serpin-proteinase complex explain the unique abil-
ity of the serpins to inhibit their cognate protein-
ases by induced destabilisation, and further con-
¢rm the biological success of the serpins as the
predominant family of serine proteinases in higher
animals.
As mentioned above, serpins possess two structur-
al elements that are conformationally labile and are
essential for e⁄cient proteinase inhibition: a reactive
centre loop and a L-sheet (L-sheet A) (Fig. 1), which
is able to open and accommodate the reactive centre
loop after its cleavage by the attacking proteases
[26,27]. The conformational mobility of these regions
also permits serpins to adopt a number of variant
conformations and assembly states under physiolog-
ical conditions, and renders them sensitive to muta-
tions, of which there are many that result in changes
in structure, biosynthesis and/or functional activity.
Many of these mutants are linked to speci¢c diseases,
Fig. 1. Schematic picture of the native K1-antitrypsin. The reactive centre (yellow), L-sheet A (red) and C-terminal peptide (dark blue)
are shown in relation to the rest of the structure (light blue).
BBADIS 62016 15-3-01 Cyaan Magenta Geel Zwart
S. Janciauskiene / Biochimica et Biophysica Acta 1535 (2001) 221^235 223
such as the mutants of antithrombin which are asso-
ciated with thrombosis [28], AAT mutants with lung
emphysema and liver diseases [29], and the mutation
in the neuroserpin that results in the polymerisation
and aggregation of the protein which is associated
with familial encephalopathy [30].
Serpin inhibitory activity is also regulated by co-
factors which are needed to expose or maintain the
reactive centre loop of some serpins. The best exam-
ple of this phenomenon is antithrombin, which is
activated by heparin through induced and transmit-
ted conformational changes that stabilise the protein-
ase-sensitive active site [31]. Another serpin, PAI-1,
which normally exists in a latent form, can be main-
tained in its functional form in the presence of plas-
ma vitronectin [32]. As well as stabilising PAI-1 in
the active conformation, vitronectin also alters the
speci¢city of PAI-1, making it an e⁄cient inhibitor
of thrombin. The ¢nding that active PAI-1 speci¢-
cally inhibits integrin attachment to vitronectin [33]
further illustrates the unique functional interdepend-
ence that exists between PAI-1 and vitronectin.
Some serpins have been found to have surprising
biological activities beyond that of protease inhibi-
tion. Nitrosylation of AAT by nitric oxide under
in£ammatory conditions generates a chemically
modi¢ed AAT with unexpected cysteine protease in-
hibitor and antibacterial activities [34]. Another ser-
pin, K1-antichymotrypsin (ACT), which is primarily
an inhibitor of cathepsin G and chymase, has been
shown to inhibit puri¢ed DNA polymerase [35] and
DNA primase [36], possibly through its strong a⁄n-
Fig. 2. Conformational polymorphism of inhibitory serpins. Schematic picture of the serpin (lilac) and reactive centre (yellow).
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ity for DNA observed in vitro. Native AAT was
shown to increase insulin-induced mitogenesis in
various ¢broblast and epithelial cell lines [37], as
well as to inhibit cell growth in human plasma [38].
This latter activity is also observed in three other
serpins, ACT, C1-esterase inhibitor and K2-antiplas-
min [38]. Clearly, serpins have multiple biological
activities in addition to their role as proteinase inhib-
itors.
Studies of the functional and conformational poly-
morphism of inhibitory serpins show that under cer-
tain physiological conditions serpins can undergo
conformational change due to mutation, chemical
modi¢cation, or to interaction with other molecular
species. Multiple forms of inhibitory serpins have
been identi¢ed in biological £uids: native inhibitory,
inactivated or latent forms, and non-inhibitor forms
such as cleaved, polymerised and oxidised (Fig. 2).
Inactivation of inhibitors is known to be mediated by
several mechanisms: through complex formation
with target protease [39], non-speci¢c cleavage by
metalloproteases [40], oxidation of the active site me-
thionine [41], and by polymerisation [20]. The loss of
inhibitory activity of serpins necessarily results in an
imbalance between proteases and their inhibitors, but
it may also have other physiological e¡ects through
the generation of abnormal concentrations of confor-
mationally modi¢ed non-inhibitory forms. For exam-
ple, it has recently been shown that antithrombin,
which functions as an inhibitor of thrombin and oth-
er enzymes, in its cleaved conformation has potent
antiangiogenic and antitumour activity in mouse
models [42]. On the other hand, the degradation of
antithrombin by tumours could explain the hyper-
coagulable state observed with many cancers [43].
Finally the generation of cleaved antithrombin pro-
vides additional evidence that plasma proteins leak-
ing from tumour vessels not only form a neostroma
for tumour growth but also mobilise angiogenesis
inhibitors such as cleaved antithrombin and angio-
statin generated from plasminogen [44].
The recognition that multiple functions and path-
ologies can arise from increased levels of di¡erent
polymorphs of the same serpin is a relatively novel
concept. Some inhibitory serpins, like K1-antitrypsin
and K1-antichymotrypsin, are well studied examples
of these phenomena and illustrate how single serpins
can play multiple roles in systemic disorders.
3. Non-inhibitory forms of K1-antitrypsin and their
role in systemic disorders
AAT is an important component of the serine pro-
teinase inhibitor system in humans, with the physio-
logical function of inhibiting target proteinases such
as neutrophil elastase and proteinase 3. It also inhib-
its other serine proteinases, including cathepsin G,
thrombin, trypsin and chymotrypsin, but with lower
e⁄ciency than that for neutrophil elastase [6,17]. The
local balance between proteinases and endogenous
inhibitors like AAT is an important factor in deter-
mining whether in£ammation results in connective
tissue damage.
AAT is synthesised primarily in the liver, but also
in extrahepatic tissues and cells, including neutro-
phils, monocytes and macrophages, alveolar macro-
phages, intestinal epithelial cells, carcinoma cells and
the cornea [45^48]. AAT is found in most tissues
and body £uids and it is an acute-phase reactant
whose plasma concentration can rise by 3^4-fold
above normal (1.34 mg/ml) during in£ammation, in-
fection and malignant diseases. In the human cornea,
its local concentration is regulated by growth factors
and might be increased up to 11-fold [48]. Although
the mechanisms responsible for the increase of AAT
are poorly understood, it has been shown that hu-
man neutrophils, monocytes and alveolar macro-
phages can increase expression of AAT in response
to in£ammatory mediators, such as interleukin-6,
bacterial lipopolysaccharide and in response to
AAT itself when complexed with neutrophil elastase
[49,50].
Many data support the widely accepted notion
that a major function of AAT is the inhibition of
overexpressed proteinases during in£ammatory pro-
cesses [51^53]. However, it is also known that the
biological activity of AAT can be a¡ected by chem-
ical modi¢cations, including inter- or intramolecular
polymerisation, oxidation, complex formation and
cleavage by non-speci¢c proteinases (Fig. 2).
3.1. Polymerisation
Molecular mobility confers on serpins the capacity
to bind and entrap their target proteinases in highly
stable complexes, but also a concomitant propensity
to form dysfunctional molecules. A single amino acid
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change in certain domains of the serpin molecule can
block changes in structure necessary for normal in-
hibitory activity and folding and can lead to poly-
merisation of mutant serpin into intracellular aggre-
gates [18,54]. A well-characterised example of a
mutant serpin associated with a disease state is
AAT, which occurs at low levels in early onset pul-
monary emphysema [2]. The most widely studied de-
¢ciency variants of AAT are Z and S, which have
E342K and E264V mutations respectively [54,55].
Polymerisation of AAT is also known to be involved
in AAT de¢ciency-related diseases such as liver cir-
rhosis, neonatal hepatitis, hepatocellular carcinoma
and lung emphysema [56^58]. These pathologies are
characterised by the formation of intracellular inclu-
sions of polymerised AAT due to sequential insertion
of the reactive loop from one AAT molecule into a
large L-sheet of another [59]. Although lung injury is
believed to occur due to the decrease in elastase in-
hibitory capacity normally provided by AAT, liver
injury is also thought to be due to the hepatotoxic
e¡ect of the abnormally folded AAT molecules re-
tained in the endoplasmic reticulum (ER) [60]. The
AAT Z variant has been demonstrated to polymerise
spontaneously at higher concentrations and increased
temperatures in vitro[61], suggesting that an increase
in body temperature during systemic in£ammation
would exacerbate this tendency in vivo.
Recently a familial encephalopathy was described
in which a mutant neuroserpin forms inclusion
bodies [62]. Interestingly, the histochemistry of the
neuroserpin aggregates, or Collins bodies, observed
in the brain were found to be very similar to the
AAT inclusions produced in the liver of those indi-
viduals expressing the Z variant [63]. Polymerisation
also occurs in variants of other members of the serine
proteinase inhibitor superfamily, such as antithrom-
bin, C1-inhibitor, and K1-antichymotrypsin, in asso-
ciation with thrombosis [64], angioedema [65], and
chronic obstructive pulmonary disease [66], respec-
tively. Cleavage of the reactive site loop at non-target
positions also promotes polymerisation of AAT [67].
This polymerisation process may play a role in amy-
loidosis, since fragments of AAT have been shown to
form L-sheet rich ¢brils in vitro [68]. There are at
least 15 human diseases associated with accumula-
tion of speci¢c proteins in insoluble polymers known
as amyloid. Understanding the mechanism and struc-
tural determinants of protein polymerisation may
open pathways to rational design of drugs to block
the protein-protein associations and thereby amelio-
rate the associated disease. Recently, a class of com-
pounds called chemical chaperones, such as 4-phe-
nylbutyric acid, has been shown to reverse the
cellular mislocalisation or misfolding of intracellular
proteins and to mediate increased secretion of mu-
tant AAT Z [69]. This might provide a pharmaco-
logical strategy for prevention of liver injury and
emphysema in AAT de¢ciency.
Beyond the attendant loss of proteinase inhibitor
activity, it is also possible that polymerised forms of
serpins have other functional activities. Polymerised
forms of various serpins have been shown to be
present in human biological £uids from various in-
£ammatory diseases, but their biological roles and
elimination rates, and their e¡ects on cellular func-
tional activities have not been de¢ned. Elucidation of
the biological activities of polymeric forms of serpins
may provide not only useful insights into the patho-
genesis of amyloid-related and other diseases, but
may also suggest therapeutic strategies.
3.2. Complex formation
AAT, like most inhibitory serpins, inhibits protein-
ases through the formation of a serpin-enzyme com-
plex (Fig. 2). AAT contains a single reactive site,
centred at a Met-Ser sequence 36 amino acid residues
from the C-terminus. Formation of a 1:1 molar com-
plex between serpin and enzyme is accompanied by
cleavage in the reactive site of the AAT and an irre-
versible conformational transition to a stable, inac-
tive form. When complexes are formed between the
serpin and its target protease, there is an accompa-
nying conformational change in the serpin that either
unmasks or causes the formation of a new binding
site in the complexed serpin that is not present in the
free serpin [49,70]. Studies by many groups have
shown that under normal physiological conditions,
the liver mediates rapid clearance from the circula-
tion of serpin-proteinase complexes, including AAT-
proteinase complexes, via several receptors, such as
the serpin-enzyme complex (SEC) receptors [71], low-
density lipoprotein (LDL) receptor [72] and very-
low-density lipoprotein (VLDL) receptor [73]. How-
ever, high levels of circulating AAT-elastase com-
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plexes have been detected in patients with lung em-
physema and rheumatic diseases [74] during acute
processes such as myocardial infarction and acute
leukaemia [75,76], and elevated levels of AAT-trypsin
complexes have been found in patients with biliary
tract cancer [77]. Thus, clearance of AAT-proteinase
complexes appears to be impaired or inadequate in
capacity in some pathological conditions, raising the
possibility that these circulating serpin-proteinase
complexes have biological functions. It was shown
that these complexes stimulate the biosynthesis of
AAT in cell cultures and are chemotactic for neutro-
phils [78]. Moreover, the observation that serpin-pro-
teinase complexes are recognised by endocytosis re-
ceptors of the LDL receptor family suggests that
those complexes may play a role in both lipid metab-
olism and proteinase activity regulation during the
in£ammatory response.
AAT is known to form complexes not only with
target proteinases, but also with other molecules.
Complexes between monoclonal immunoglobulin
light chains of U type and AAT have been found in
serum from patients with myeloma and Bence-Jones
proteinemia [79], and factor XIa-AAT and AAT-glu-
cose complexes are common in plasma from diabetic
subjects [80]. Disulphide linked complexes between
immunoglobulin A (IgA) and AAT are detected at
low levels in the sera of healthy volunteers, but are
found at increased levels in the sera and synovial
£uid of patients with rheumatoid arthritis (RA), sys-
temic lupus erythematosus and ankylosing spondyli-
tis [81]. Recently it has been suggested that alteration
in AAT structure might be an important factor in
promoting IgA-AAT complex formation, since
AAT damaged by heating and low pH as occurs in
normal urine, is able to complex more rapidly with
IgA [82]. However, the reason for increased IgA-
AAT formation in the circulation of patients with
RA is still unknown. Prostate-speci¢c antigen
(PSA), itself a kallikrein-ACT complex, which corre-
lates with prostate hypertrophy and malignancy, is
also known to be bound to AAT in sera of subjects
with high PSA concentrations [83]. These ¢ndings
suggest that further unexpected causal links may ex-
ist between serpin complex formation with speci¢c
ligands, alterations in functional activity, and the
pathological processes characterised by such complex
formation.
3.3. Cleavage
Cleaved AAT is another non-inhibitory form
found in vivo, whose other biological roles have re-
ceived little attention (Fig. 2). Cleaved forms of AAT
are know to occur when AAT forms an inhibitor
complex with serine proteinase which subsequently
dissociates or is degraded, or when it is cleaved by
non-target proteinases, usually at sites in its reactive
site, without formation of stable inhibitor complexes.
Such cleavages generate a 4 kDa carboxyl-terminal
fragment of 36 residues, which remains non-cova-
lently bound to the cleaved AAT. Human cathepsin
L, collagenase and stromelysin, and bacterial pro-
teinases from Staphylococcus aureus, Serratia marces-
cens metalloproteinase and Pseudomonas aeruginosa
elastase [84] all fall into the latter class and exhibit
e⁄cient AAT degrading activity. Recent studies es-
tablished AAT as a key substrate for gelatinase B
(MMP-9) in vivo [85]. It has long been hypothesised
that neutrophil elastase-mediated tissue destruction
in certain in£ammatory diseases such as emphysema,
is caused by an imbalance in the ratio of elastase to
AAT [86]. The studies of Liu and collaborators pro-
vide in vivo evidence that this mechanism, mediated
by the proteolytic inactivation of AAT by gelatinase
B, underlies the pathology of an in£ammatory skin
disorder called bullous pemphigoid, that is initiated
by deposit formation at the basement membrane
[85,87]. Generated cleaved forms of AAT may con-
tribute to the later phase of polymorphonuclear leu-
cocyte in¢ltration. Indeed, cleaved AAT was shown
to be a potent chemoattractant for monocytes [88].
Recently, the structure of a cleaved polymer of AAT
was found to con¢rm the ¢rst proposed model of
serpin polymerisation [89^91]. Moreover, two dis-
tinct L-sheet interactions (A- and C-sheet) of the
cleaved AAT were observed in the polymers, and it
was suggested that the A L-sheet interaction is likely
to be important in serpin polymer formation, while
the C L-sheet interaction may provide a possible ex-
planation for serpin interaction with other proteins.
Polymers of AAT and other serpins have been ob-
served in vivo. Lomas and co-workers showed that Z
AAT polymerised in vitro has identical properties
and ultrastructure to the inclusions isolated from he-
patocytes of a Z homozygote [92], but there are no
other available data that identify intact or cleaved
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serpin is involved in formation of various polymers.
Therefore further studies are needed to establish
which form of serpin is involved in polymer forma-
tion under various pathophysiological conditions.
3.4. Degradation
Cleaved, carboxyl-terminal fragments of AAT
arising from non-target proteolytic cleavage were
found to be present in human bile and in a variety
of human tissues, such as placenta, pancreas, stom-
ach and small intestine [46,93^95]. Increased levels of
fragmented AAT in oral tissue and £uids were found
in subjects with insulin-dependent diabetes mellitus
(IDDM) who had been clinically diagnosed as having
periodontal disease [96]. Also, the carboxyl-terminal
fragment of AAT created by reactive site cleavage
was found to be associated with extracellular matrix
proteins such as collagen and/or laminin-1, and it
was suggested that this AAT peptide plays an impor-
tant role in the protection of these proteins from
inappropriate enzyme digestion [97]. We know from
various studies that the carboxyl-terminal segment
remains ¢rmly attached to the core of cleaved AAT
and to the cleaved AAT in complex with enzyme
[70,88]. Although the peptide is non-covalently
bound to the remaining molecule of AAT, it can
only be separated under denaturing condition
[67,94,98]. This raises the question of how degrada-
tion fragments of serpins, like the carboxyl-terminal
fragment of cleaved AAT, can be generated in free
form. In vitro studies have shown that serpin-pro-
teinase complexes are unstable, their rate of break-
down apparently dependent on their structure and
environmental conditions. This increased susceptibil-
ity of serpin-proteinase complex to proteolytic deg-
radation could be one possible source of the AAT
fragments. Also, native AAT and, in particular, oxi-
dised AAT, are known to be good substrates for
metalloproteinases [84,85]. The cleavages of AAT
by these proteinases might generate fragments of
AAT. Endocytosis of serpins and serpin-proteinase
complexes could also give rise to their degradation,
with exocytosis of peptide fragments. Although these
speculations remain to be proven, the fact that the
peptide(s) of AAT can be detected in vivo con¢rms
their dissociation from the parent serpin.
We have examined the e¡ects of proteolytically
cleaved AAT and the amyloidogenic carboxy-termi-
nal fragment of AAT on hepatoma cells and mono-
cyte cultures [99,100], and showed that these forms
of AAT exert signi¢cant e¡ects on cellular lipid ca-
tabolism and proin£ammatory activation. These
forms of AAT were also found to activate peroxi-
some proliferator-activated receptors (PPARs), tran-
scription factors that recently have been proposed to
regulate genes for lipid metabolism and proin£am-
matory proteins [100]. Furthermore, we determined
that the carboxy-terminal cleavage fragment of AAT
is a component of atherosclerotic plaque, located
speci¢cally in the ¢brous cap near the necrotic core
[100]. The proteolytic inhibitors AAT and K2-macro-
globulin have been shown to be present in relatively
high concentrations in human aortic atherosclerotic
lesions, and it has been suggested that these proteins
could enhance ¢brosis of the lesion because of their
known inhibitory e¡ects on elastase and collagenase
[101,102]. Consistent with this, plasma levels of AAT
are correlated with the development of both early
and advanced atherosclerosis in the carotid arteries
[103].
The mechanism by which AAT contributes to pro-
gressive coronary atherosclerosis is unknown, but it
appears to accompany tissue injury and vascular in-
£ammation, conditions which are mediated by a
complex network of molecular interactions and in-
creased expression of acute-phase proteins, including
AAT. It is likely that proteinase inhibitory activity of
AAT can be compromised by chemical modi¢cations
attendant on the in£ammatory state, and the modi-
¢ed form(s) of AAT may also play a role in athero-
genesis. The observed biological activities of the
cleaved forms of AAT suggest that the role of
AAT in the pathology of atherosclerosis is not only
as an inhibitor of proteases, but also as a protease
substrate and a reservoir of physiologically active
peptide degradation products. Since atherosclerosis
appears to be a chronic in£ammatory process in
the vessel wall in response to injury, the markedly
increased biosynthesis of AAT during in£ammation
might give rise to a large fraction of cleaved/de-
graded forms of AAT. A proteinase-induced imbal-
ance in favour of the latter could play a critical role
in lesion progression.
Production of AAT by tumour cells has been re-
ported [47,104], and earlier observations that AAT-
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positive adenocarcinomas of colon and lung have a
worse prognosis than AAT-negative ones [105] sug-
gest that AAT may also play a role in cancer. Malig-
nant cells are characterised by their ability to spread
and invade normal tissues. Both of these processes
involve proteolytic activities of malignant cells which
detach the cell and degrade extracellular matrices.
The proteases involved in these processes which
have been characterised so far, include metallopro-
teinases (MMPs) produced by both the cancer cells
and the surrounding host tissue. Since AAT is pro-
duced by various tumour cells and is a good sub-
strate for MMPs [84,85], one can speculate that there
is a link between MMP activity, tumour cell propen-
sity to produce and secrete AAT, and tumour
growth. Recent studies provide good experimental
evidence that the C-terminal fragment of AAT gen-
erated by matrix metalloproteinases enhances tu-
mour growth and invasiveness in vivo [106].
Together, these observations support the notion
that under in£ammatory conditions AAT may play
a role not only as an inhibitor of proteases, but also
as a protease substrate and a reservoir of physiolog-
ically active peptide degradation products. Studies
also suggest that non-inhibitory forms of AAT, par-
ticularly the cleaved and/or degraded forms, may
have yet unde¢ned biological activities in in£amma-
tory processes, such as atherosclerosis and cancero-
genesis. Demonstration that serpins, including native
and cleaved AAT molecules, form polymers, leads to
the speculation that this polymerisation might con-
duce to both generation of biologically active pep-
tides and to amyloid formation in amyloid-related
diseases in which serpins are known to be involved.
3.5. Oxidation
Oxidation of methionine (Met) has been shown to
a¡ect a number of biologically active proteins [107].
Met oxidation may lead to an increase in biological
activity, in case of the C5 component of complement
[108], or to no apparent change in structure or activ-
ity in case of K2-plasmin inhibitor [109]. It has also
been shown that oxidation of the two most suscep-
tible Met in another serpin, antithrombin, does not
inactivate the protein nor a¡ect its ability to bind
heparin [107]. Oxidised AAT is a modi¢ed form of
AAT often found in in£ammatory exudates at levels
of about 5^10% that of total AAT [110]. The amino
acid at position P1 in the reactive site of each inhib-
itory serpin primarily determines the speci¢city of
inhibition and thereby its biological activity. P1 in
AAT is Met, the most readily oxidised amino acid
of proteins, which is converted by oxidation to me-
thionine sulphoxide [111]. Met can be attacked by
various oxidants produced in biological systems,
such as peroxide, hydroxyl radicals, hypochloride,
chloramines and peroxynitrite [112]. It has been
shown that levels of active circulating AAT can be
reduced in normal, healthy individuals by enzymatic
oxidation of the reactive site methionine of AAT by
neutrophil myeloperoxidase. Also, oxidative inactiva-
tion of the AAT can be induced in vitro by incubat-
ing AAT with puri¢ed myeloperoxidase or stimu-
lated phagocytes [113]. Evidence that this occurs in
vivo comes from the observation that inactive AAT
puri¢ed from in£ammatory synovial £uid contains
methionine sulphoxide residues [114]. Some bacteria
can also exploit the oxidation of AAT. This is ap-
parent for S. marcescens and S. aureus metallopro-
teinases, which cleave oxidised AAT signi¢cantly
faster than native [115]. Thus, oxidation and proteo-
lytic processes in some cases may work synergistical-
ly to promote local in£ammation, including uncon-
trolled degradation of connective tissues. That AAT
oxidation and proteolysis do occur in vivo is sup-
ported by ¢ndings that, on average, 41% of total
AAT in rheumatoid arthritis synovial £uid is inac-
tive, oxidised and/or cleaved [116]. Recently it has
been shown that oxidation of AAT promotes AAT-
immunoglobulin A complex formation in vitro. IgA-
oxidised AAT complexes isolated from synovial £uid
of rheumatoid disease patients were suggested to
protect the oxidised AAT molecule from proteolytic
cleavage by free elastase [81,117], and to be impor-
tant in maintaining the balance of proteinase and
antiproteinase levels during in£ammation, especially
if dissociation of IgA-oxidised AAT complex can oc-
cur under conditions that lead to reactivation of oxi-
dised AAT.
Oxidative inactivation of AAT with subsequent
enhanced proteolysis, particularly by neutrophil elas-
tase, has been invoked in the pathogenesis of pulmo-
nary emphysema in smokers [118^120]. AAT recov-
ered in bronchial lavage £uid from human and rat
lungs after exposure to cigarette smoke shows it to
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contain methionine sulphoxide residues and to have
diminished inhibitory capacity. Similarly, lavage £uid
from the lungs of smokers showed 2-fold diminution
in AAT activity relative to that from non-smokers
[119,121,122].
Leucocytes, neutrophils and macrophages, which
secrete large quantities of oxidants at sites of in£am-
mation, were shown to induce oxidative inactivation
of AAT in vivo and to result in perturbed protease-
antiprotease balance. Although oxidised AAT plays
a proin£ammatory role at sites of in£ammation be-
cause of its loss of inhibitor activity toward pro-
teases, it cannot be excluded that oxidised AAT
may also have other biological activities related to
in£ammation. Using primary human monocytes cul-
tures, we have found that oxidised AAT induces
monocyte activation and alterations in cholesterol
homeostasis [123], which provides evidence that gen-
eration of oxidised AAT in in£ammatory loci may
play a role in modulating in£ammatory responses.
4. Serpins in neurodegenerative brain diseases
Interest in serine and cysteine proteinases and their
serpin inhibitors, and their roles in the pathogenesis
of neurodegenerative diseases has expanded recently,
because these proteinases and their inhibitors were
detected at sites of neuronal injury. Numerous stud-
ies have been conducted to determine the role of
serine proteases and serpins in physiologic and
pathologic conditions. Serine proteinases have been
detected in neurones and in glial cells of the central
nervous system (CNS) and shown to regulate the
balance of accumulation and degradation of the
extracellular matrix. For example, the serine protein-
ase thrombin was shown to protect astrocytes against
hypoglycaemia or oxidative stress, but to increase
neuronal death, while tissue-type plasminogen activa-
tor (t-PA) was shown to protect neurones against
Zn-induced cell death, but to mediate neuronal death
induced by excitotoxins [124^126].
It is inferred from di¡erent studies that expression
of serine proteinases is modulated during brain in-
jury and that an impairment in the balance between
serine proteinases and their cognate inhibitors in the
CNS may lead to a pathologic state [125,127]. There-
fore, the levels of expression of native and chemically
modi¢ed forms of serpins may be important in
understanding various neurodegenerative conditions.
It has been reported that the expression of the type 1
PAI and protease nexin-1 (PN-1) is increased in the
cerebrospinal £uid from patients with neurologic dis-
orders, such as Alzheimer’s disease (AD), cerebral
infarction, CNS infection and neoplasia [125]. In-
creased levels of other members of the serpin family,
such as antithrombin, an inhibitor of the blood co-
agulation cascade, and ACT, an inhibitor of protein-
ases of the chymotrypsin class, were also found in
AD plaques [128,129]. Several observations have sug-
gested that serpin levels might in£uence the outcome
of brain injury. For example PAI-1 produced by as-
trocytes was found to be neuroprotective against ne-
crosis mediated N-methyl-D-aspartate [130]. PN-1
was reported to protect cultured neurones from glu-
cose deprivation-induced damage through attenua-
tion of the increase in intracellular calcium levels
associated with such damage [131].
Neuroserpin is a newly identi¢ed member of the
serpin family that is primarily expressed in brain, and
primarily localised to neurones [132]. Neuroserpin is
believed to play a vital role in controlling extracellu-
lar proteolysis in the nervous system, especially as an
inhibitor of tissue-type plasminogen activator [133].
As such, neuroserpin is also suggested to be an im-
portant factor contributing to neuronal plasticity and
learning [134]. Recently it was shown that mutations
in the neuroserpin gene result in polymerisation and
aggregation of the neuroserpin protein, with conse-
quent diminution in neuroserpin levels, which might
result in uncontrolled proteolysis and the loss of neu-
ronal function [135,136]. On the other hand, it is
equally conceivable that the inclusion bodies formed
from the aggregated neuroserpin, so-called Collins
bodies [62], themselves are neurotoxic. The newly
described familial encephalopathy with neuroserpin
inclusion bodies provides additional suggestive evi-
dence that the inclusion bodies themselves have
pathological e¡ects.
5. K1-Antichymotrypsin: link to Alzheimer’s disease
A link between ACT and AD was established by
the observation that ACT is present in both amor-
phous and classic plaques of AD and in amyloid
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deposits in Down’s syndrome and normally aged
brains [137,138]. ACT is an acute phase protein
and a serpin proteinase inhibitor, which is synthe-
sised primarily by hepatocytes, bronchial epithelial
cells, activated astrocytes and to a small extent by
monocytes [139^141]. ACT appears to speci¢cally in-
activate neutrophil cathepsin G, mast cell chymase
and pancreatic chymotrypsin [142]. In addition, it
has been shown to reduce the natural killing activity
of T-cell lymphocytes and to inhibit superoxide gen-
eration by human neutrophils [143]. The major frac-
tion of immunologically identi¢able human prostate
derived proteases, used clinically to monitor patients
with prostate cancer, is found in complex with ACT
[144].
To determine the state in which ACT is deposited
in amyloid plaques, monoclonal antibodies against
ACT that can distinguish native ACT from com-
plexed and inactive were used, and it was found
that ACT in both amorphous and classic plaques is
either complexed or proteolytically inactive [145].
ACT, like other serpins, is characterised by a mobile
reactive site and a dominant L-sheet A which can
open to insert the cleaved active site loop (Fig. 1).
The intact serpins can also take up exogenous free
peptides of the same or similar sequence as their
reactive site sequence into L-sheet A upon incubation
with excess peptide [146]. Such an interaction results
in inactivation and polymerisation of serpin. AD
amyloid plaques are composed primarily of variants
of the L-amyloid protein (AL), which is a proteolytic
fragment of the larger L-amyloid precursor protein
[147]. We and others have shown that ACT forms
extremely stable complexes with AL1ÿ42, comparable
in speci¢city and stability to a proteinase-inhibitor
interaction, and that it also inhibits or accelerates
¢brillisation of AL1ÿ42 [148^150]. Furthermore, the
binding of AL to ACT renders ACT inactive as a
proteinase inhibitor. Thus, ACT acts as a molecular
chaperone to in£uence ¢bril formation through spe-
ci¢c complexes with AL1ÿ42, and AL1ÿ42 reciprocally
abolishes ACT inhibitor activity. The loss of ACT
inhibitor activity implies dysregulation of protein-
ase(s) at foci of AL biosynthesis, these proteinases
being elevated during in£ammation associated with
AD.
ACT-chymotrypsin complexes regulate neutrophil
superoxide production [143] and AAT-proteinase
complex has neutrophil chemoattractant activity
and upregulates synthesis of AAT [78]. The complex
of AL1ÿ42 with ACT structurally resembles that of
serpin-proteinase complexes, and since the latter
have biological activities beyond that of proteinase
inhibition, it is possible that ACT-AL1ÿ42 complexes
also have as yet undiscovered biological activities
which contribute to the establishment of self-propa-
gating neurotoxic pathologies. ACT-proteinase com-
plexes and/or ACT-AL complex may feedback upreg-
ulate ACT biosynthesis, which by raising local ACT
levels in the presence of increasing AL could sustain
pathological cycles [151]. Proteinase targets of ACT
which are unregulated as a result of AL blockage of
ACT inhibitor activity could include proteinases as-
sociated with AL1ÿ42 biosynthesis or degradation,
and also proteinases linked to cytokine activity. It
was recently shown that ACT can indirectly inhibit
a proteinase which degrades AL1ÿ42 [148].
Serine proteinases and their inhibitors are exten-
sively involved in in£ammatory processes related to
neurodegenerative diseases. Little is known about the
metabolic fate and biological activities of ACT-pro-
teinase complexes and nothing about non-inhibitory
ACT-AL complexes, but the notion that these com-
plexes play roles in neurodegenerative disease merits
further attention.
6. Conclusion
Virtually all proteins function by interacting with
other molecules and these interactions may alter the
physical, biochemical and functional properties of
the proteins. The capacity to undergo conformation-
al change is crucial for the physiological function of
many proteins, and the serpins are a clear case where
such changes have been exploited during evolution as
a means of modulating inhibitory activity. This ver-
satility of structure and function may also explain
how in complex environments the serpins have be-
come the predominant proteinase inhibitors in higher
organisms. The chemical reactivity, molecular struc-
ture and physical properties of serpins permit these
proteins to adopt a number of variant conformations
and assembly states under physiological conditions.
In£ammatory exudates contain serine proteinase in-
hibitors in diverse molecular forms, including a na-
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tive inhibitory form and several inactive, non-inhib-
itory forms, such as complexes with protease or other
ligands, cleaved, polymerised and oxidised. Although
these forms of inhibitory serpins are detected in tis-
sues and £uids recovered from in£ammatory sites,
the important questions of which conditions result
in generation of di¡erent molecular forms of serpins,
what biological function these forms have, and which
of them are directly linked to pathologies and/or may
be useful markers for characterisation of disease
state, remain to be answered. On the other hand,
an appreciation that one and the same serpin is
able to perform multiple functions dependent on its
molecular form will be necessary to achieve an
understanding of new important roles of serpins in
the coming years.
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